Page results
-
Until this point, if a largely over estimated total daily dose was entered by the user incorrectly, there is a risk of over delivery of insulin during Auto mode. This risk is the highest on the first day and reduces gradually over subsequent days.
-
In the UK in 2020, 23 million Novo Nordisk FlexPen and FlexTouch pre-filled devices were incinerated or sent to landfill as there was no viable recycling alternative.
-
UCLH is reminding staff that gloves are not always required, by reducing the instances where non-sterile plastic gloves are used when treating non-infectious patients. The focus is now on how clean hands are just as effective a barrier against infection.
-
Five UCLH consultants have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to biomedical and health science and their ability to generate new knowledge and improve the health of people everywhere.
-
The psychology team will be running this 8-week online parent mindfulness group for parents of children and young people under a medical team at UCLH.
-
The UCLH@Home service is helping patients like 55-year-old Sherena Kranat to continue their recovery in their own home under the care of their hospital team.
-
Martin Jacobs joined UCLH as a non-executive director on 1 January 2020. He spent 20 years with PricewaterhouseCoopers (PwC) where he was a Partner within the Corporate Finance division.
-
Our specialist myeloma team holds four myeloma outpatient clinics per week, seeing over 300 patients every month.
-
This page has been written for patients who are having a course of radiotherapy for a brain tumour called a meningioma.
-
Myelodysplastic syndrome (MDS), or myelodysplasia, is a blood disorder that causes a drop in your number of healthy blood cells.
File results
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2019/77 Discharge and readmittance for patients with no fixed abode
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide